Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses

Amy S. Paller

doi:10.1016/j.jid.2018.08.027

Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses

Amy S. Paller^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Review article › peer-review

27 Scopus citations

Abstract

Despite extensive discovery about the mutations underlying genetic skin disorders, there have been few therapeutic advances. Better understanding of the molecular changes that may lead to the phenotypic manifestations of genetic disorders may lead to the discovery of new pharmacologic interventions. The ichthyoses are characterized by scaling, inflammation, and an impaired epidermal barrier. Recent studies have uncovered T helper type 17 skewing in ichthyotic skin, resembling psoriasis, and high frequencies of IL-17– and IL-22–expressing T cells in blood, correlating with severity and transepidermal water loss. Repurposing systemic T helper type 17/IL-23–inhibitory therapies for psoriasis may prove useful for patients with ichthyosis.

Original language	English (US)
Pages (from-to)	535-540
Number of pages	6
Journal	Journal of Investigative Dermatology
Volume	139
Issue number	3
DOIs	https://doi.org/10.1016/j.jid.2018.08.027
State	Published - Mar 2019

Funding

The Montagna Symposium is an National Institutes of Health-supported conference (grant no. R13-AR009431-52; principal investigator, Kulesz-Martin); Thanks to Emma Guttman-Yassky, James Krueger, Tali Czarnowicki, Patrick Brunner, and many others for their collaboration in discovering the biomarkers in skin and blood associated with ichthyosis. The Montagna Symposium is an National Institutes of Health -supported conference (grant no. R13-AR009431-52 ; principal investigator, Kulesz-Martin); Thanks to Emma Guttman-Yassky, James Krueger, Tali Czarnowicki, Patrick Brunner, and many others for their collaboration in discovering the biomarkers in skin and blood associated with ichthyosis.

ASJC Scopus subject areas

Biochemistry
Molecular Biology
Dermatology
Cell Biology

Access to Document

10.1016/j.jid.2018.08.027

Cite this

@article{f1239f98e0c34e70a8afd7787a437721,

title = "Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses",

abstract = "Despite extensive discovery about the mutations underlying genetic skin disorders, there have been few therapeutic advances. Better understanding of the molecular changes that may lead to the phenotypic manifestations of genetic disorders may lead to the discovery of new pharmacologic interventions. The ichthyoses are characterized by scaling, inflammation, and an impaired epidermal barrier. Recent studies have uncovered T helper type 17 skewing in ichthyotic skin, resembling psoriasis, and high frequencies of IL-17– and IL-22–expressing T cells in blood, correlating with severity and transepidermal water loss. Repurposing systemic T helper type 17/IL-23–inhibitory therapies for psoriasis may prove useful for patients with ichthyosis.",

author = "Paller, {Amy S.}",

note = "Publisher Copyright: {\textcopyright} 2018 The Author",

year = "2019",

month = mar,

doi = "10.1016/j.jid.2018.08.027",

language = "English (US)",

volume = "139",

pages = "535--540",

journal = "Journal of Investigative Dermatology",

issn = "0022-202X",

publisher = "Elsevier B.V.",

number = "3",

}

TY - JOUR

T1 - Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses

AU - Paller, Amy S.

PY - 2019/3

Y1 - 2019/3

N2 - Despite extensive discovery about the mutations underlying genetic skin disorders, there have been few therapeutic advances. Better understanding of the molecular changes that may lead to the phenotypic manifestations of genetic disorders may lead to the discovery of new pharmacologic interventions. The ichthyoses are characterized by scaling, inflammation, and an impaired epidermal barrier. Recent studies have uncovered T helper type 17 skewing in ichthyotic skin, resembling psoriasis, and high frequencies of IL-17– and IL-22–expressing T cells in blood, correlating with severity and transepidermal water loss. Repurposing systemic T helper type 17/IL-23–inhibitory therapies for psoriasis may prove useful for patients with ichthyosis.

AB - Despite extensive discovery about the mutations underlying genetic skin disorders, there have been few therapeutic advances. Better understanding of the molecular changes that may lead to the phenotypic manifestations of genetic disorders may lead to the discovery of new pharmacologic interventions. The ichthyoses are characterized by scaling, inflammation, and an impaired epidermal barrier. Recent studies have uncovered T helper type 17 skewing in ichthyotic skin, resembling psoriasis, and high frequencies of IL-17– and IL-22–expressing T cells in blood, correlating with severity and transepidermal water loss. Repurposing systemic T helper type 17/IL-23–inhibitory therapies for psoriasis may prove useful for patients with ichthyosis.

UR - http://www.scopus.com/inward/record.url?scp=85060083303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060083303&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2018.08.027

DO - 10.1016/j.jid.2018.08.027

M3 - Review article

C2 - 30670307

AN - SCOPUS:85060083303

SN - 0022-202X

VL - 139

SP - 535

EP - 540

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

IS - 3

ER -

Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this